Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 64

Similar articles for PubMed (Select 23413112)

2.
4.
5.

Rilpivirine. First-line treatment of HIV infection: efavirenz is better documented.

[No authors listed]

Prescrire Int. 2012 Nov;21(132):262-5.

PMID:
23210255
6.

Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection.

Deeks ED, Perry CM.

Drugs. 2010 Dec 3;70(17):2315-38. doi: 10.2165/11203800-000000000-00000. Review.

PMID:
21080746
7.

Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection.

Bernardini C, Maggiolo F.

Patient Prefer Adherence. 2013 Jun 19;7:531-42. doi: 10.2147/PPA.S28797. Print 2013.

8.

Rilpivirine: a new addition to the anti-HIV-1 armamentarium.

Miller CD, Crain J, Tran B, Patel N.

Drugs Today (Barc). 2011 Jan;47(1):5-15. doi: 10.1358/dot.2011.47.1.1583188. Review.

PMID:
21373646
9.

Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.

Allavena C, Dailly E, Reliquet V, Bonnet B, Pineau S, André-Garnier E, Boutoille D, Bouquié R, Raveleau A, Bouchez S, Billaud E, Raffi F.

J Antimicrob Chemother. 2014 Oct;69(10):2804-8. doi: 10.1093/jac/dku187. Epub 2014 Jun 6.

PMID:
24907142
10.

The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.

Kulkarni R, Babaoglu K, Lansdon EB, Rimsky L, Van Eygen V, Picchio G, Svarovskaia E, Miller MD, White KL.

J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):47-54. doi: 10.1097/QAI.0b013e31823aca74.

PMID:
21997204
11.

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.

Kabbara WK, Ramadan WH.

J Infect Public Health. 2015 May 19. pii: S1876-0341(15)00087-8. doi: 10.1016/j.jiph.2015.04.020. [Epub ahead of print] Review.

PMID:
26001757
12.

Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor.

James C, Preininger L, Sweet M.

Am J Health Syst Pharm. 2012 May 15;69(10):857-61. doi: 10.2146/ajhp110395.

PMID:
22555080
13.

Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.

Gantner P, Reinhart S, Partisani M, Baldeyrou M, Batard ML, Bernard-Henry C, Cheneau C, de Mautort E, Priester M, Fafi-Kremer S, Muret P, Rey D.

HIV Med. 2015 Feb;16(2):132-6. doi: 10.1111/hiv.12183. Epub 2014 Aug 15.

PMID:
25124291
14.

Emtricitabine/tenofovir disoproxil fumarate.

[No authors listed]

Drugs R D. 2004;5(3):160-1. Review.

PMID:
15139777
15.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
16.
17.

Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.

Crauwels H, van Heeswijk RP, Stevens M, Buelens A, Vanveggel S, Boven K, Hoetelmans R.

AIDS Rev. 2013 Apr-Jun;15(2):87-101. Review.

PMID:
23681436
18.

An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients.

Putcharoen O, Kerr SJ, Ruxrungtham K.

HIV AIDS (Auckl). 2013 Sep 16;5:231-41. doi: 10.2147/HIV.S25712. Review.

19.

Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era.

De Clercq E.

Biochem Pharmacol. 2012 Aug 1;84(3):241-8. doi: 10.1016/j.bcp.2012.03.024. Epub 2012 Apr 5. Review.

PMID:
22504027
20.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk